Structure Therapeutics Stock Rises on Positive Clinical Trial Results

Structure Therapeutics shares are trading higher after the company reported positive topline data from its ACCESS program for the oral GLP-1 receptor agonist, Aleniglipron, demonstrating significant weight loss in clinical trials and plans to advance to Phase 3 development.